COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
19/05/2026
Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production MELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: [...]
Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib
19/05/2026
HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study Focus on investigating new, daily dosing of narmafotinib in combination with standard [...]
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
19/05/2026
-- STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. -- Study to evaluate tertiary [...]
Transactions in connection with share buy-back program
19/05/2026
Company announcement no. 17 - 26 19 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative
19/05/2026
Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative 2026 Surviving [...]
FEATOL Introduces Ergonomic Wrist Support for Modern Repetitive Strain Challenges
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- FEATOL has introduced the FEATOL 2 Pack Carpal Tunnel Wrist Brace, a wrist support solution for daily stabilization, pain relief, and recovery support. The brace is made for [...]
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
GenoSafe advances CLIA pathway for transatlantic ATMP development
19/05/2026
GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens [...]
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
19/05/2026
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on the numerical [...]
SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
19/05/2026
BRUSSELS, May 19, 2026 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire [...]
ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026
19/05/2026
EINDHOVEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence [...]
Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue
19/05/2026
SON4PEM trial advances development of sonlicromanol, aiming to address chronic fatigue in Post-COVID patients with post-exertional malaise NIJMEGEN, The Netherlands, May 19, 2026 (GLOBE NEWSWIRE) -- Khondrion today [...]
Unaudited Preliminary Results for the Year Ended December 31, 2025
19/05/2026
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery [...]
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
19/05/2026
Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to [...]
Fangzhou Ranked among 2025 Guangzhou AI Innovation “Most Promising Enterprises” for AI‑Powered Chronic Disease Services
19/05/2026
GUANGZHOU, China, May 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, was invited to attend the 2026 Guangzhou [...]
Rapid Nutrition Advances Finalization of Australian Flagship Initiative
19/05/2026
LONDON, May 19, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company focused on evidence-based nutrition brands, is pleased to provide an update regarding its Australian [...]
Pennant Group to Participate in the 2026 RBC Global Healthcare Conference
19/05/2026
EAGLE, Idaho, May 18, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will [...]
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
18/05/2026
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfa normalized [...]

Pages